Oritavancin

DB04911ApprovedInvestigationalSmall moleculeLipoglycopeptide Antibacterial

Oritavancin is an antibacterial agent used to treat acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria. It was developed by The Medicines Company (acquired by Novartis).

Mechanism: The cell wall is vital for the survival and replication of bacteria, making it a primary target for antibiotic therapy. Oritavancin works against susceptible gram-positive organisms via three separate mechanisms. Firstly, it binds to the stem peptide of peptidoglycan precursors, inhibiting transglycosylation (polymerization). This process normally occurs during cell wall synthesis. Secondly, oritavancin inhibits crosslinking during bacterial cell wall biosynthesis via binding to cell wall pentaglycyl peptide bridging segments. Finally, this drug also acts by disrupting the bacterial cell membrane, interfering with its integrity, which eventually leads to cell death by various mechanisms.
Curator reviewed · 4 references
Primary indication: Oritavancin is indicated for the treatment of adult patients with acute bacterial skin and skin structure (including subcutaneous) infection.Curator reviewed · 2 structured indications
Formula / weight: C₈₆H₉₇Cl₃N₁₀O₂₆ · 1793.101 g/mol (avg)
First approval: United States, 2014 · European Union, 2020
Code names: LY-333328
Brand names: Kimyrsa
Orbactiv
Tenkasi

Resolves to

Compound

UNIIPUG62FRZ2ECAS171099-57-3ChEMBLCHEMBL1688530ChEBI82699PubChem16136912KEGGC12034

Clinical / RWD

RxNorm1547611ATCJ01XA05

Structure

InChIKeyVHFGEBVPHAGQPI-LXKZPTCJSA-NSMILES

CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(NCC5=CC=C(C=C5)C5=CC=C(Cl)C=C5)[C@@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2

Targets

P0AC13folP

What you can answer from here — as of September 13, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

642Drug interactionsStructured to mechanism, not free text

16Clinical trialsPhase, status and sponsor resolved per trial

2Structured indicationsCondition, population, route and combination as fields, not prose

2ContraindicationsEach with its own population and attribute set

8Marketed productsAcross 3 countries and 3 labellers

1ATC codeIncluding every combination product, plus 28 drug categories

37+ReferencesStructured and connected to the statements they support

Which drugs share a target with Oritavancin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account